{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:57:18Z","timestamp":1793145438606,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02363761"],"award-info":[{"award-number":["RF-2016-02363761"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02363761"],"award-info":[{"award-number":["RF-2016-02363761"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2019-2020"],"award-info":[{"award-number":["Ricerca Corrente 2019-2020"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2019-2020"],"award-info":[{"award-number":["Ricerca Corrente 2019-2020"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00787-020-01582-9","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T08:30:58Z","timestamp":1593678658000},"page":"21-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression"],"prefix":"10.1007","volume":"31","author":[{"given":"Marco","family":"Pozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Ida","family":"Ferrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scrinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nobile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Bravaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1056\/NEJMsa1413512","volume":"372","author":"M Olfson","year":"2015","unstructured":"Olfson M, Druss BG, Marcus SC (2015) Trends in mental health care among children and adolescents. N Engl J Med 372:2029\u20132038","journal-title":"N Engl J Med"},{"key":"1582_CR2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0004867412463169","volume":"47","author":"V Eapen","year":"2013","unstructured":"Eapen V, Shiers D, Curtis J (2013) Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication. Aust N Z J Psychiatry 47:435\u2013442","journal-title":"Aust N Z J Psychiatry"},{"key":"1582_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13052-016-0259-2","volume":"42","author":"S Pisano","year":"2016","unstructured":"Pisano S, Catone G, Veltri S et al (2016) Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr 42:51","journal-title":"Ital J Pediatr"},{"key":"1582_CR4","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.4088\/JCP.15m10247","volume":"77","author":"M Pozzi","year":"2016","unstructured":"Pozzi M, Pisano S, Bertella S et al (2016) Persistence in therapy with risperidone and aripiprazole in pediatric outpatients: a 2-year naturalistic comparison. J Clin Psychiatry 77:1601\u20131609","journal-title":"J Clin Psychiatry"},{"key":"1582_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2016.1229301","volume":"15","author":"C Rafaniello","year":"2016","unstructured":"Rafaniello C, Pozzi M, Pisano S et al (2016) Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 15:1\u20138","journal-title":"Expert Opin Drug Saf"},{"key":"1582_CR6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/cap.2010.0020","volume":"22","author":"LA Kryzhanovskaya","year":"2012","unstructured":"Kryzhanovskaya LA, Xu W, Millen BA et al (2012) Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 22:157\u2013165","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR7","first-page":"11","volume":"42","author":"RA Baker","year":"2009","unstructured":"Baker RA, Pikalov A, Tran QV et al (2009) Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 42:11\u201331","journal-title":"Psychopharmacol Bull"},{"key":"1582_CR8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/obr.12561","volume":"18","author":"O Ajala","year":"2017","unstructured":"Ajala O, Mold F, Boughton C et al (2017) Childhood predictors of cardiovascular disease in adulthood. A systematic review and meta-analysis. Obes Rev 18:1061\u20131070","journal-title":"Obes Rev"},{"key":"1582_CR9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","volume":"34","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Ching H, Patten S (2011) Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 34:651\u2013668","journal-title":"Drug Saf"},{"key":"1582_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40272-013-0016-6","volume":"15","author":"NB Almandil","year":"2013","unstructured":"Almandil NB, Liu Y, Murray ML et al (2013) Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs 15:139\u2013150","journal-title":"Paediatr Drugs"},{"key":"1582_CR11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M De Hert","year":"2011","unstructured":"De Hert M, Dobbelaere M, Sheridan EM et al (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144\u2013158","journal-title":"Eur Psychiatry"},{"key":"1582_CR12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.psychres.2007.07.008","volume":"157","author":"I Tarricone","year":"2008","unstructured":"Tarricone I, Serretti A, Gozzi BF et al (2008) Metabolic side effects of second generation antipsychotic agents in antipsychotic-na\u00efve patients: one-month prospective evaluation. Psychiatry Res 157:269\u2013271","journal-title":"Psychiatry Res"},{"key":"1582_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/eip.12251","volume":"10","author":"C Tek","year":"2016","unstructured":"Tek C, Kucukgoncu S, Guloksuz S et al (2016) Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 10:193\u2013202","journal-title":"Early Interv Psychiatry"},{"key":"1582_CR14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"1582_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7:64\u201377","journal-title":"Lancet Psychiatry"},{"key":"1582_CR16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M et al (2018) Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol 28:659\u2013674","journal-title":"Eur Neuropsychopharmacol"},{"key":"1582_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000853","author":"S Wakefield","year":"2019","unstructured":"Wakefield S, Aligeti M, Rachamallu V et al (2019) Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers. Am J Ther. https:\/\/doi.org\/10.1097\/MJT.0000000000000853","journal-title":"Am J Ther"},{"key":"1582_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpsychires.2017.12.002","volume":"97","author":"N Sugawara","year":"2018","unstructured":"Sugawara N, Sagae T, Yasui-Furukori N et al (2018) Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: a randomized controlled trial. J Psychiatr Res 97:77\u201383","journal-title":"J Psychiatr Res"},{"key":"1582_CR19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10597-017-0203-y","volume":"54","author":"KM Bozymski","year":"2018","unstructured":"Bozymski KM, Whitten JA, Blair ME et al (2018) Monitoring and treating metabolic abnormalities in patients with early psychosis initiated on antipsychotic medications. Community Ment Health J 54:717\u2013724","journal-title":"Community Ment Health J"},{"key":"1582_CR20","doi-asserted-by":"crossref","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","volume":"9","author":"M Bak","year":"2014","unstructured":"Bak M, Fransen A, Janssen J et al (2014) Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE 9:e94112","journal-title":"PLoS ONE"},{"key":"1582_CR21","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013, https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"1582_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","volume":"41","author":"G Ratzoni","year":"2002","unstructured":"Ratzoni G, Gothelf D, Brand-Gothelf A et al (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337\u2013343","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1582_CR23","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V et al (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765\u20131773","journal-title":"JAMA"},{"key":"1582_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1753-2000-8-18","volume":"8","author":"ML Menard","year":"2014","unstructured":"Menard ML, Th\u00fcmmler S, Auby P, Askenazy F (2014) Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. Child Adolesc Psychiatry Ment Health 8:18","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"1582_CR25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1399-5618.2010.00797.x","volume":"12","author":"C Moreno","year":"2010","unstructured":"Moreno C, Merch\u00e1n-Naranjo J, Alvarez M et al (2010) Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 12:172\u2013184","journal-title":"Bipolar Disord"},{"key":"1582_CR26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/cap.1998.8.151","volume":"8","author":"DL Kelly","year":"1998","unstructured":"Kelly DL, Conley RR, Love RC et al (1998) Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8:151\u2013159","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/cap.2000.10.259","volume":"10","author":"A Martin","year":"2000","unstructured":"Martin A, Landau J, Leebens P et al (2000) Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10:259\u2013268","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2000.10.79","volume":"10","author":"A Zuddas","year":"2000","unstructured":"Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000) Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79\u201390","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4088\/JCP.v64n0909","volume":"64","author":"G Masi","year":"2003","unstructured":"Masi G, Cosenza A, Mucci M, Brovedani P (2003) A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039\u20131047","journal-title":"J Clin Psychiatry"},{"key":"1582_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/104454604773840490","volume":"14","author":"R Kant","year":"2004","unstructured":"Kant R, Chalansani R, Chengappa KN, Dieringer MF (2004) The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder. J Child Adolesc Psychopharmacol 14:57\u201363","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2007.0138","volume":"18","author":"J Castro-Fornieles","year":"2008","unstructured":"Castro-Fornieles J, Parellada M, Soutullo CA et al (2008) Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 18:327\u2013336","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","volume":"69","author":"D Fraguas","year":"2008","unstructured":"Fraguas D, Merch\u00e1n-Naranjo J, Laita P et al (2008) Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166\u20131175","journal-title":"J Clin Psychiatry"},{"key":"1582_CR33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/cap.2010.0011","volume":"20","author":"G Roy","year":"2010","unstructured":"Roy G, Bedard A, Desmarais PA et al (2010) Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-na\u00efve French Canadian patients. J Child Adolesc Psychopharmacol 20:479\u2013487","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.clnu.2011.03.007","volume":"30","author":"C Cuerda","year":"2011","unstructured":"Cuerda C, Merchan-Naranjo J, Velasco C et al (2011) Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. Clin Nutr 30:616\u2013623","journal-title":"Clin Nutr"},{"key":"1582_CR35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/JCP.0b013e31822befa9","volume":"31","author":"H Demb","year":"2011","unstructured":"Demb H, Valicenti-McDermott M, Navarro A, Ayoob KT (2011) The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder. J Clin Psychopharmacol 31:669\u2013670","journal-title":"J Clin Psychopharmacol"},{"key":"1582_CR36","first-page":"177","volume":"28","author":"L Margari","year":"2013","unstructured":"Margari L, Matera E, Craig F et al (2013) Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol 28:177\u2013183","journal-title":"Int Clin Psychopharmacol"},{"issue":"1179\u201390","key":"1582_CR37","first-page":"1190.e1","volume":"53","author":"C Arango","year":"2014","unstructured":"Arango C, Gir\u00e1ldez M, Merch\u00e1n-Naranjo J et al (2014) Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-na\u00efve patients. J Am Acad Child Adolesc Psychiatry 53(1179\u201390):1190.e1\u20134","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1582_CR38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00787-016-0866-x","volume":"26","author":"I Baeza","year":"2017","unstructured":"Baeza I, Vigo L, de la Serna E et al (2017) The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. Eur Child Adolesc Psychiatry 26:35\u201346","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1582_CR39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/0706743717718166","volume":"62","author":"D Ilies","year":"2017","unstructured":"Ilies D, Huet AS, Lacourse E et al (2017) Long-term metabolic effects in french-canadian children and adolescents treated with second-generation antipsychotics in monotherapy or polytherapy: a 24-month descriptive retrospective study. Can J Psychiatry 62:827\u2013836","journal-title":"Can J Psychiatry"},{"key":"1582_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/cap.2017.0117","volume":"28","author":"I Baeza","year":"2018","unstructured":"Baeza I, de la Serna E, Calvo-Escalona R et al (2018) One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: is there a link with metabolic syndrome? J Child Adolesc Psychopharmacol 28:463\u2013473","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/cap.2018.0092","volume":"29","author":"M Pozzi","year":"2019","unstructured":"Pozzi M, Pisano S, Marano G et al (2019) Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting. J Child Adolesc Psychopharmacol 29:133\u2013140","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR42","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00702-008-0105-9","volume":"115","author":"C Fleischhaker","year":"2008","unstructured":"Fleischhaker C, Heiser P, Hennighausen K et al (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm (Vienna) 115:1599\u20131608","journal-title":"J Neural Transm (Vienna)"},{"key":"1582_CR43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pediatrneurol.2009.04.002","volume":"41","author":"RS Degrauw","year":"2009","unstructured":"Degrauw RS, Li JZ, Gilbert DL (2009) Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. Pediatr Neurol 41:183\u2013186","journal-title":"Pediatr Neurol"},{"key":"1582_CR44","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jadohealth.2012.10.272","volume":"52","author":"SR Ghate","year":"2013","unstructured":"Ghate SR, Porucznik CA, Said Q et al (2013) Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health 52:336\u2013343","journal-title":"J Adolesc Health"},{"key":"1582_CR45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/cap.1999.9.93","volume":"9","author":"E Szigethy","year":"1999","unstructured":"Szigethy E, Wiznitzer M, Branicky LA et al (1999) Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9:93\u201398","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e3182962480","volume":"33","author":"A Noguera","year":"2013","unstructured":"Noguera A, Ballesta P, Baeza I et al (2013) Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol 33:463\u2013471","journal-title":"J Clin Psychopharmacol"},{"key":"1582_CR47","first-page":"877","volume":"55","author":"LA Nussbaum","year":"2014","unstructured":"Nussbaum LA, Dumitra\u015fcu V, Tudor A et al (2014) Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom J Morphol Embryol 55:877\u2013884","journal-title":"Rom J Morphol Embryol"},{"key":"1582_CR48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/eip.12083","volume":"8","author":"B O'Donoghue","year":"2014","unstructured":"O'Donoghue B, Sch\u00e4fer MR, Becker J et al (2014) Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Interv Psychiatry 8:276\u2013280","journal-title":"Early Interv Psychiatry"},{"key":"1582_CR49","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/JCP.0000000000000688","volume":"37","author":"E Matera","year":"2017","unstructured":"Matera E, Margari L, Palmieri VO et al (2017) Risperidone and cardiometabolic risk in children and adolescents: clinical and instrumental issues. J Clin Psychopharmacol 37:302\u2013309","journal-title":"J Clin Psychopharmacol"},{"key":"1582_CR50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/19315864.2010.542274","volume":"4","author":"JA Hellings","year":"2011","unstructured":"Hellings JA, Boehm D, Yeh HW et al (2011) Long-term aripiprazole in youth with developmental disabilities including autism. J Ment Health Res Intellect Disabil 4:40\u201352","journal-title":"J Ment Health Res Intellect Disabil"},{"key":"1582_CR51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/cap.2014.0111","volume":"25","author":"K Dominick","year":"2015","unstructured":"Dominick K, Wink LK, McDougle CJ, Erickson CA (2015) A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol 25:397\u2013401","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/cap.2013.0099","volume":"24","author":"LK Wink","year":"2014","unstructured":"Wink LK, Early M, Schaefer T et al (2014) Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol 24:78\u201382","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/070674371506001005","volume":"60","author":"R Ronsley","year":"2015","unstructured":"Ronsley R, Nguyen D, Davidson J, Panagiotopoulos C (2015) Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study. Can J Psychiatry 60:441\u2013450","journal-title":"Can J Psychiatry"},{"key":"1582_CR54","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/cap.2016.0171","volume":"27","author":"CP Sjo","year":"2017","unstructured":"Sjo CP, Stenstr\u00f8m AD, Bojesen AB et al (2017) Development of metabolic syndrome in drug-naive adolescents after 12 months of second-generation antipsychotic treatment. J Child Adolesc Psychopharmacol 27:884\u2013891","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/cap.2018.0111","volume":"29","author":"RJ Schoemakers","year":"2019","unstructured":"Schoemakers RJ, van Kesteren C, van Rosmalen J et al (2019) No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. J Child Adolesc Psychopharmacol 29:192\u2013196","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","volume":"19","author":"CA Calarge","year":"2009","unstructured":"Calarge CA, Acion L, Kuperman S et al (2009) Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19:101\u2013109","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR57","first-page":"110","volume":"2","author":"N Del Castillo","year":"2013","unstructured":"Del Castillo N, Zimmerman MB, Tyler B et al (2013) 759C\/T variants of the serotonin (5-HT2C) receptor gene and weight gain in children and adolescents in long-term risperidone treatment. Clin Pharmacol Biopharm 2:110","journal-title":"Clin Pharmacol Biopharm"},{"key":"1582_CR58","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1089\/cap.2016.0049","volume":"26","author":"Y Yoon","year":"2016","unstructured":"Yoon Y, Wink LK, Pedapati EV et al (2016) Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. J Child Adolesc Psychopharmacol 26:822\u2013827","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1582_CR59","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2215-0366(17)30166-9","volume":"4","author":"AK Pagsberg","year":"2017","unstructured":"Pagsberg AK, Jeppesen P, Klauber DG et al (2017) Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry 4:605\u2013618","journal-title":"Lancet Psychiatry"},{"key":"1582_CR60","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1651-2227.2011.02370.x","volume":"100","author":"B Brannsether","year":"2011","unstructured":"Brannsether B, Roelants M, Bjerknes R, J\u00fal\u00edusson PB (2011) Waist circumference and waist-to-height ratio in Norwegian children 4\u201318 years of age: reference values and cut-off levels. Acta Paediatr 100:1576\u20131582","journal-title":"Acta Paediatr"},{"key":"1582_CR61","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/1740774512453218","volume":"9","author":"TA Trikalinos","year":"2012","unstructured":"Trikalinos TA, Olkin I (2012) Meta-analysis of effect sizes reported at multiple time points: a multivariate approach. Clinical Trials 9:610\u2013620","journal-title":"Clinical Trials"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-020-01582-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-020-01582-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-020-01582-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T17:02:48Z","timestamp":1643994168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-020-01582-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s00787-020-01582-9","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest concerning the topic of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}